Journals
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 10 of 10
2021-06-14 [p.1099]
Q-666 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the government's use of Switch Health for post-arrival coronavirus tests for travellers: (a) what are the service standards in terms of distributing, picking up, and processing tests; (b) what are the service standards for responding to client inquiries or complaints; (c) in what percentage of cases did Switch Health meet or exceed service standards; (d) for cases where standards were not met, what was the reason given; (e) how many of the required post-arrival tests were never completed; (f) of the tests in (e), what is the breakdown by reason (Switch Health unable to provide service in Spanish, traveler refusal, etc.); (g) was there a competitive bid process for the contract awarded to Switch Health and, if so, who were the other bidders; and (h) what are the details of all meetings, including telephone or virtual, that Switch Health had with the government prior to the awarding of the contract, including the (i) date, (ii) names and titles of representatives from Switch Health, (iii) names and titles of government representatives, including any ministerial staff? — Sessional Paper No. 8555-432-666.
2021-04-26 [p.827]
Q-513 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the National Advisory Committee on Immunization (NACI) and Health Canada respectively: (a) what scientific evidence, expert opinions, and other factors went into the decision to extend the dosing schedule up to four months between doses of the COVID-19 vaccines; and (b) what is the summary of the minutes of each meeting the NACI had in which dosing timelines were discussed? — Sessional Paper No. 8555-432-513.
2021-04-26 [p.828]
Q-514 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the Public Health Agency of Canada (PHAC): (a) how many doctors and other designated medical professionals have been employed by the agency, broken down by year since 2015; and (b) what percentage of PHAC employees do each of the numbers in (a) represent? — Sessional Paper No. 8555-432-514.
2021-01-25 [p.446]
Q-292 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the Prime Minister's announcement in May 2020 of an agreement with CanSino Biologics Inc. (CanSinoBIO) in relation to the development of a potential COVID-19 vaccine: (a) what were the original details of the agreement, as understood by the government in May 2020; (b) on what date did the government first become aware that the agreement would not proceed as planned; (c) on what date did the government become aware that shipments of Ad5-nCoV were being blocked by the Chinese government; (d) what reason, if any, did the Chinese government provide to the government for blocking the shipment; (e) has the government transferred any money or any type of expenditures to CanSinoBIO since January 1, 2020, and, if so, what is the total amount sent, broken down by date of transfer; (f) what are the details of any contracts signed with CanSinoBIO since January 1, 2020, including the (i) amount, (ii) original value, (iii) final value, (iv) date the contract was signed, (v) description of goods or services, including volume; (g) was the National Security and Intelligence Advisor to the Prime Minister advised of the terms agreement prior to the Prime Minister's announcement, and, if so, did he approve of the agreement; (h) was the Department of National Defence or the Canadian Security Intelligence Service informed of the details of the agreement prior to the Prime Minister's announcement, and, if so, did they raise any concerns with the Office of the Prime Minister or the Privy Council Office; and (i) what were the results of any security analysis conducted in relation to CanSinoBIO? — Sessional Paper No. 8555-432-292.
2020-11-18 [p.283]
Q-109 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the organization and structure of the Public Health Agency of Canada (PHAC): (a) what was the organizational structure of PHAC, including a breakdown of how many employees or full-time equivalents working in each branch, location and in each position, as of (i) January 1, 2016, (ii) October 1, 2020; and (b) what are the details of the positions that have been eliminated or modified since January 1, 2016, including the (i) previous job title, (ii) new job title, if applicable, (iii) previous job description, (iv) new job description, (v) number of positions impacted, (vi) date the position was eliminated or modified, (vii) number of previous positions eliminated, if applicable? — Sessional Paper No. 8555-432-109.
2020-11-18 [p.284]
Q-110 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to drug products currently awaiting approval and market authorization by Health Canada: (a) what is the complete list of products currently awaiting approval; (b) for each product in (a), what was the (i) date the application was received by the government, (ii) manufacturer, (iii) product name, (iv) summary of product claims, including the list of diseases and conditions the product claims to treat, (v) expected date of decision of approval by Health Canada, if known; and (c) has the time period between the date of application and the decision date by Health Canada, for non-COVID-19 related products increased as a result of reallocating resources during the pandemic, and, if so, what are the specific details, including for which applications and for which products the time period has increased? — Sessional Paper No. 8555-432-110.
2020-01-27 [p.108]
Q-220 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to expenditures on single-use bottled water by the government in fiscal years 2017-18, 2018-19 and to date in 2019-20: (a) what are the total expenditures, broken down by department or agency; (b) what are the details of all such expenditures, including (i) date, (ii) amount, (iii) vendor, (iv) description of goods, including quantity, (v) reason the bottled water was purchased; and (c) of the expenditures in (b), which expenditures were incurred for consumption in facilities where access to safe drinking water was readily available? — Sessional Paper No. 8555-431-220.
2020-01-27 [p.108]
Q-221 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to grants and contributions under $25,000 provided by Innovation, Science and Economic Development Canada, and the 17 federal departments and agencies that make up the innovation, science and economic development portfolio, since January 1, 2018: what are the details of each, including (i) date of funding, (ii) recipient, (iii) location, (iv) project description? — Sessional Paper No. 8555-431-221.
2020-01-27 [p.108]
Q-222 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to contracts under $10,000 granted by Innovation, Science and Economic Development Canada, and the 17 federal departments and agencies that make up the innovation, science and economic development portfolio, since January 1, 2018: what are the (i) vendors' names and locations, (ii) contracts' reference and file numbers, (iii) dates of the contracts, (iv) descriptions of the goods or services provided, (v) delivery dates, (vi) original contracts' values, (vii) final contracts' values, if different from the original contracts' values? — Sessional Paper No. 8555-431-222.
2020-01-27 [p.108]
Q-223 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to Innovation, Science and Economic Development Canada, and the 17 federal departments and agencies that make up the innovation, science and economic development portfolio, and broken down by year since the 2016-17 fiscal year: (a) what was the total amount spent on (i) travel for government employees, (ii) travel for stakeholders; (iii) travel for individuals who are neither government employees nor stakeholders, (iv) hospitality; and (b) what are the details of all travel for stakeholders, including (i) date of travel, (ii) cost of trip, broken down by flight cost, accommodation costs and other costs, (iii) name of stakeholder, (iv) organization represented, if applicable? — Sessional Paper No. 8555-431-223.
Results: 1 - 10 of 10

Export As: XML CSV RSS

For more data options, please see Open Data